Maurade Gormley, MSN, Gail D’Eramo Melkus, EdD, ANP, FAAN, and Allison Vorderstrasse, APRN, DNSc, MSN, RN, New York University College of Nursing, New York, NY;
Bradley E. Aouizerat, PhD, New York University College of Dentistry, New York, NY;
Tish Knobf, PhD, RN, AOCN, FAAN, Yale University School of Nursing, New Haven, CT; and
Marilyn Hammer, PhD, DC, RN, Mount Sinai Hospital Department of Nursing, New York, NY
The purpose of this research is to learn how the results of your Oncotype Dx® test results affect your health-related quality of life; your feelings of distress, anxiety, depression, and fear; and your perceived risk of recurrence. The researchers will use these findings to develop a personalized symptom management program to help improve the quality of life of breast cancer survivors. The research team wanted to enroll up to 130 participants.
The initial Call to Action for this study was sent to AOW members on August 7, 2019 and the researchers closed enrollment on January 2, 2020. The AOW provided them with 138 women who were interested in enrolling in the study.
To view the researcher’s presentation of the study’s findings, click here.